Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 875 versus DYNAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 875 versus DYNAPEN.
AUGMENTIN '875' vs DYNAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Dynapen (dicloxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
One 875 mg amoxicillin/125 mg clavulanate tablet orally every 12 hours.
250-500 mg orally every 6 hours for skin and soft tissue infections; up to 500 mg every 6 hours for respiratory tract infections.
None Documented
None Documented
Amoxicillin: 1-1.5 hours (may extend to 7-13 hours in renal impairment). Clavulanate: ~1 hour (may extend to 2.5-4.5 hours in renal impairment).
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria.
Amoxicillin: ~50-70% renal as unchanged drug, 10-20% biliary. Clavulanate: ~30-50% renal as unchanged, ~25% fecal.
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic